Trial Profile
A randomised, double-blind, placebo-controlled Phase II study to target the type I IFN receptor by administrating Anifrolumab in RA patients with a high IFN signature (TarIFNiRA)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 03 Feb 2022
Price :
$35
*
At a glance
- Drugs Anifrolumab (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms TarIFNiRA
- 24 Dec 2020 Status changed from recruiting to discontinued.
- 27 Feb 2020 Planned End Date changed from 27 Dec 2019 to 1 Mar 2021.
- 27 Feb 2020 Planned primary completion date changed from 27 Dec 2019 to 1 Mar 2021.